β-blockers after percutaneous coronary intervention does not reduce risks of all-cause mortality or major adverse cardiovascular events in patients with stable coronary artery disease
GAO Xiyu
XIAO Jing
FENG Na
GUO Chen
CAO Lifei
ZHANG Chunyan
ZHANG Yan
HAN Tuo
Abstract：Objective To explore the association between the use of β-blockers and the risks of all-cause mortality and major adverse cardiovascular events(MACEs)in patients with stable coronary artery disease(SCAD)after percutaneous coronary intervention(PCI).Methods We performed secondary analyses of the data of 55 SCAD patients receiving post-PCI β-blocker treatment and 149 patients without post-PCI β-blockers(control group)from the Dryad database.The clinical and coronary artery disease characteristics of the patients were analyzed,and propensity score matching was used to compare all-cause mortality and MACEs(including cardiovascular death,non-fatal myocardial infarction and non-fatal stroke)between the two groups.Results The overall patients(69.6%were male)had a mean age of 72.6±10.3 years with a median follow-up time of 783 days.A total of 18 patients(8.8%)died,and MACEs occurred in 19 patients(9.3%),including cardiovascular death in 6 cases(2.9%),non-fatal myocardial infarction in 3 cases(1.5%)and non-fatal stroke in 11 cases(5.4%).In the β-blocker group,deaths occurred in 5 cases(9.1%),and MACEs in 4 cases(7.3%),including 2 cases with cardiovascular death(3.6%)and 2 cases with non-fatal stroke(3.6%).Kaplan-Meier survival curve analysis showed that the use of β-blockers after PCI was not associated with a reduced all-cause mortality(8.7%vs 9.1%,log-rank P=0.870)or incidence of MACEs(10.1%vs 7.3%,log-rank P=0.510)either before or after adjusting for age,sex,aspartate aminotransferase,estimated glomerular filtration rate,left ventricular ejection fraction,and history of atrial fibrillation(HR=0.81,95%CI:0.24-2.72;HR=0.62,95%CI:0.22-1.69).No significant differences were found in all-cause death or MACEs between the two groups after propensity score adjustment,matching,or IPTW inverse probability weighting(all P>0.05).Conclusion Routine use of β-blockers after PCI does not reduce the incidence of all-cause death or MACEs in patients with SCAD.
Keywords：stable coronary artery diseasepercutaneous coronary interventionβ-blockersall-cause mortalitymajor adverse cardiovascular events
Publication Date：2026-01-20
Online Publishing Date：2026-01-22(First online date of this platform, not the publication date of the document)
Pages：7( 159-165 )